United States · Industrial & Consumer Products · USD · Annual
Reported figures and Equlion model projections for the next 5 years.
Sector average
Sector average (own scale)
Amounts in USD; stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for Pasithea Therapeutics Corp.? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Key metrics | Actual | Forecast | ||||
|---|---|---|---|---|---|---|
| Metric | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
| ROE | -29.68% | -50.7% | -132.63% | 368.55% | 84.84% | 46.31% |
|---|---|---|---|---|---|---|
| Sector average | -4.6% | 22.2% | -36.22% | -229.04% | -10.73% | -40.81% |
| ROA | -28.3% | -46.74% | -88.12% | -121.68% | -123.43% | -115.53% |
| Gross Margin | 76.74% | 76.67% | 77.2% | 77.71% | 77.91% | 78.03% |
| Total Assets | $45,180,089.00 | $28,370,754.41 | $17,441,198.89 | $19,409,062.74 | $21,882,812.12 | $22,749,296.48 |
| Sector average | $13,660,548,977.01 | $12,843,948,419.06 | $12,594,656,237.49 | |||
| Net Income | -$13,936,452.00 | -$17,188,021.89 | -$20,183,642.49 | -$22,419,540.80 | -$25,482,275.59 | -$25,781,091.69 |
| $13,470,792,028.32 |
| $13,845,953,105.56 |
| $15,738,337,670.39 |